A Phase Ib Study of the Safety, Tolerability and Efficacy of BT02 for the Treatment of Patients With Advanced Malignant Melanoma
Latest Information Update: 13 Aug 2025
At a glance
- Drugs BT 02 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors BioTroy Therapeutics
Most Recent Events
- 13 Aug 2025 New trial record